PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
August 15, 2025CancerOpen Access

Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSun Young RhaECEduardo CastañónSGSanjeev Gill

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows 20% objective response rate in recurrent glioblastoma, indicating lenvatinib and pembrolizumab may offer a new treatment option.

Key Points

  • Lenvatinib plus pembrolizumab showed antitumor activity in patients with recurrent glioblastoma.
  • Of the 101 participants, the objective response rate was 20%, with a median duration of response of 3.7 months.
  • Participants received lenvatinib daily and pembrolizumab every three weeks, regardless of tumor PD-L1 status.
  • The treatment was generally well tolerated, but 41% experienced severe treatment-related adverse events.

Cite This Study

Rha et al. (2025) studied this question.

synapsesocial.com/papers/689fc6912abb084d53ed27cbhttps://doi.org/10.1002/cncr.70015
View Full Paper
Ask AI
Bookmark
Share